Citius Pharmaceuticals, Inc.
Price Action
Technical Summary
DOWNTRENDCitius Pharmaceuticals, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 14), showing significant lag compared to the market leaders. Earnings growth of 74% provides fundamental context to the price action. Investors should exercise caution due to high volatility (131% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.78 | -14.30% | BELOW |
| 50 SMA | $0.80 | -16.29% | BELOW |
| 100 SMA | $0.83 | -19.39% | BELOW |
| 150 SMA | $0.99 | -32.92% | BELOW |
| 200 SMA | $1.07 | -37.62% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CTXR in an uptrend right now?
CTXR has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.
Is CTXR overbought or oversold?
CTXR's RSI (14) is 43. The stock is in neutral territory, neither overbought nor oversold.
Is CTXR outperforming the market?
CTXR has a Relative Strength (RS) Rating of 14 out of 99. CTXR is currently lagging the broader market.
Where is CTXR in its 52-week range?
CTXR is trading at $0.67, which is 27% of its 52-week high ($2.48) and 5% above its 52-week low ($0.57).
How volatile is CTXR?
CTXR has a Beta of 2.76 and 52-week volatility of 131%. It's more volatile than the S&P 500 - expect bigger swings.